Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form and HIPAA document~* Willing and able to comply with all study procedures~* Be at least 18 years of age at the time of enrollment~* 20/40 vision, or better, in each eye~* History of ocular allergies, and a positive skin and ocular allergic reaction to allergens~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~Exclusion Criteria:~* Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, clinically significant blepharitis, follicular conjunctivitis and iritis)~* Have had any ocular infection within the last 30 days~* A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)~* Any significant illness that could be expected to interfere with study parameters~* Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye~* Use of any investigational product or device within one month prior to Visit 1 or during the study period~* Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial or within the washout period~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of autoimmune disease, immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis~* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1~* Known history of alcohol abuse and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.1% Lifitegrast (Type: EXPERIMENTAL): None
- 1.0% Lifitegrast (Type: EXPERIMENTAL): None
- 5.0% Lifitegrast (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).